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The aim of this work was to evaluate the eﬃcacy and safety of intralesional injection of 5-ﬂuorouracil and bleomycin in the treatment
of keloids and hypertrophic scars. One hundred and twenty patients were divided into the following groups: group IA was injected
intralesionally with 5-ﬂuorouracil; group IB was injected intralesionally with a combination of triamcinolone acetonide and
5-ﬂuorouracil; group II was injected intralesionally with bleomycin. Patients underwent follow up by photographing and Vancouver scar
scale system. There was a signiﬁcant improvement in the Vancouver scar scale in group II compared to group I after treatment. There
was hyperpigmentation, pain and ulceration in all the studied groups. Pain was signiﬁcantly decreased in group IB compared to that in
group IA, ulceration was signiﬁcantly decreased in group II than in group I while pain after injection was increased in group II than in
group I. Relapse occurred in 12 patients of group IA, 14 patients of group IB and no relapse occurred in group II. So, intralesional
injection of bleomycin was more eﬀective and better in remission than intralesional 5-ﬂuorouracil injection in the treatment of keloids
and hypertrophic scars regardless of patient’s age, sex, disease duration or site of the lesion.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Bleomycin; Fluorouracil; Keloids; Hypertrophic scars1. Introduction
Keloids and hypertrophic scars are characterized by
excessive deposition of dermal collagen with resultant scarhttp://dx.doi.org/10.1016/j.jdds.2015.07.003
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Production and hosting by Elseviertissue. A keloid scar is benign, non-contagious and some-
times accompanied by severe itching, sharp pains and
changes in texture. In severe cases, it can aﬀect movement
of skin and may ulcerate. The probability of recurrence of
keloids after surgical removal is high, usually greater than
50% (Hunasgi et al., 2013; Maghrabi and Kabel, 2014).
Five-Fluorouracil (5-FU) is a pyrimidine analog, which
is used in the treatment of cancer. It is also used in oph-
thalmic surgery, speciﬁcally to augment trabeculectomy
in patients deemed to be at high risk for failure. 5-FU acts
as an anti-scarring agent in this regard, since excessive scar-
ring at the trabeculectomy site is the main cause for failure
of the surgery (Rothman et al., 2000). Recent trials havebehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
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some types of basal cell carcinomas of the skin. Some stud-
ies had used 5-FU intralesionally in the treatment of
keloids and hypertrophic scars alone or mixed with triam-
cinolone acetonide (TAC). The latter is thought to decrease
pain and inﬂammation (Davison et al., 2009).
Bleomycin is a glycopeptide antibiotic that is widely
used as an anti-cancer agent. The drug is used in the treat-
ment of Hodgkin lymphoma, squamous cell carcinomas
and testicular cancer, as well as in the treatment of plantar
warts (Lewis and Nydorf, 2006). Also, bleomycin has been
tried intralesionally to treat keloids and hypertrophic scars.
The commonest complication of bleomycin injection was
hyperpigmentation, which was seen in 75% of patients
(Saray and Gu¨lec¸, 2005). This work was a trial to evaluate
the eﬃcacy and safety of intralesional injection of
5-ﬂuorouracil and bleomycin in the treatment of keloids
and hypertrophic scars.
2. Methods
2.1. Location
This study was conducted at dermatology, venereology
and andrology department, faculty of medicine, Benha
University, Egypt. This study was approved by the
Research Ethics Board at Benha University. This work
complied with the principles laid down in the Declaration
of Helsinki.
2.2. Study design
2.2.1. Equipments
 A 1 ml insulin syringe with a ﬁxed 30 gauge needle.
 Mepivacaine HCl 3% (Mepacaine ampoule, Alexandria
Pharmaceutical Co., Egypt).
 Five-ﬂuorouracil (Fluorouracil 250 mg ampoule,
Biosynthesis Pharmaceutical Co., Egypt).
 Bleomycin (Bleocip 15 mg vial, Cipla Co. Ltd, Verna
industrial state, Goa, India).
 Triamcinolone acetonide (Kenacort vial, Bristol-Myers
Squibb).
This study was conducted on one hundred and twenty
patients with keloids and hypertrophic scars of varying
sizes and durations selected from the Dermatology and
Andrology outpatient clinic of faculty of medicine, Benha
University, Egypt.
2.2.2. Inclusion criteria
A minimum age of 15 years, acceptable pretreatment
laboratory studies (complete blood cell count, serum
chemistries, urine analysis, and pregnancy test) and a
written consent was taken from each patient before the
study.2.2.3. Exclusion criteria
Pregnancy, lactation, chronic renal failure and any
abnormalities of liver function tests or complete blood
count.
2.2.4. Groups
The patients were divided into the following groups:
Group (IA): included thirty patients who were injected
intralesionally with 5-FU at a concentration of 50 mg/ml.
Initially, local anesthetic Mepivacaine HCl 3% was admin-
istered at the lesion site. Then, the patients were injected
intralesionally with 5-ﬂuorouracil at a concentration of
50 mg/ml, multiple injections were given at 1 cm intervals
on average, 0.2–0.4 ml/cm2. The maximum dose was 2 ml
per session with a two week interval (Kontochristopoulos
et al., 2005).
Group (IB): included thirty patients who were injected
intralesionally with a mixture of 0.1 ml of 40 mg/ml TAC
and 0.9 ml of 5-FU (50 mg/ml). Initially, local anesthetic
(Mepivacaine HCl 3%) was administered at the lesion site.
Then, the patients were injected intralesionally with a mix-
ture of 0.1 ml of 40 mg/ml triamcinolone acetonide and
0.9 ml of 5-FU (50 mg/ml), multiple injections were given
at 1 cm intervals on average, 0.2–0.4 ml/cm2. The maximum
dose was 2 ml per session with a two week interval (Asilian
et al., 2006).
Group (II): included sixty patients who were injected
intralesionally with bleomycin at a concentration of
1.5 IU/ml. Initially, local anesthetic (Mepivacaine HCl
3%) was administered at the lesion site. Then, multiple
intralesional injections of bleomycin at a dose of
0.5–1 ml/cm2 with a maximum dose of 4 ml per session
using insulin syringe were administered with a two week
interval (Espan˜a et al., 2001).
All patients were subjected to complete history taking
and dermatological examination included site, size, shape,
color and consistency of the lesion. Investigations into
blood count, liver and kidney functions were done before
treatment and then at a monthly interval during therapy.
The patients were informed about the nature of each pro-
cedure, expected number of treatments and also expected
side eﬀects of the procedure. Follow up of the patients
was performed by the Vancouver scar scale system after
stopping the treatment for 12 months.
2.3. Assessment of the clinical response
Assessment of keloids was done at the beginning of the
treatment, at 4, 8, and 12 weeks, and during the follow up
period. The assessment included clinical changes in the
keloids by photographs and by reporting any side eﬀects
that the patients experienced. Clinical assessment was car-
ried out using Vancouver scar scale that includes vascular-
ity, pigmentation, pliability and height. The results were
recorded from (0) to (14) where (0) reﬂected normal skin
(Baryza and Baryza, 1995). The clinical improvement was
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tion and height as well as softening of the scar and
improvement of symptoms.2.4. Statistical analysis
Data were presented as mean ± standard deviation
(SD). An ANOVA and Student’s t-test were used for eval-
uating the statistical signiﬁcance of diﬀerences in means.
Pearson’s correlation coeﬃcient (r) was applied to correlate
between the parameters. A P value of less than 0.05 was
considered to be statistically signiﬁcant.6
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The ages of the patients ranged from 16 to 54 years with
mean values of (29.87), (32.07) and (31.5) in group (IA),
(IB) and (II) respectively The duration of the lesions ranged
from 4 months to 23 months. The most commonly aﬀected
sites were chest, shoulder, back, forearm and neck.0
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Figure 2. Vancouver scar scale in the studied groups.3.1. Number of sessions required for patient groups
In group IA, the numbers of intralesional injections of
5-FU received ranged from 4 to 6 sessions. In group IB,
the numbers of intralesional injections of 5-FU mixed with
TAC ranged from 5 to 6 sessions. In group II, the numbers
of intralesional injections of bleomycin received ranged
from 2 to 6 sessions. The diﬀerence was statistically signif-
icant compared to that of group I (IA and group IB). This
means that bleomycin is more eﬀective than 5FU alone or
mixed with TAC (Fig. 1).3.2. Vancouver scar scale in the studied groups
In group IA, the mean Vancouver scar scale in all
patients before treatment was 9.67 ± 1.35 and it was
4.47 ± 1.3 after treatment with a mean total improvement
of 54%. In group IB, the mean Vancouver scar scale in
all patients before treatment was 9.67 ± 1.63 and it was0
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Figure 1. The number of sessions required for the studied groups.4.46 ± 1.55 after treatment with a mean total improvement
of 55%. In group II, the mean Vancouver scar scale in all
patients before treatment was 9.32 ± 1.46 and it was
2.7 ± 0.95 after treatment with a mean total improvement
of 73%. The mean value of group II after treatment was
statistically signiﬁcant compared to that of group I after
treatment (Figs. 2–5).
3.3. Correlation between age, sex, disease duration and
clinical response
There was no correlation between age, sex, disease dura-
tion and clinical response in all groups (Table 1).Figure 3a. Case 7 keloid before treatment, Vancouver scale score = 12.
Figure 3b. Keloid after 6 sessions of treatment with 5-FU, Vancouver
scale score = 6, 50% improvement.
Figure 4a. Case 14 hypertrophic scar before treatment, Vancouver scale
score = 11.
Figure 4b. Hypertrophic scar after 5 sessions of bleomycin, Vancouver
scale score = 2, 81.82% improvement.
Figure 5a. Case 20 hypertrophic scar before treatment, Vancouver scale
score = 11.
Figure 5b. Hypertrophic scar after 6 sessions of 5FU +TAC, Vancouver
scale score = 5, 54.55% improvement.
Table 1
Correlation between clinical response and age, sex and disease duration in
all studied groups.
Parameter Pearson value P-value
Age 0.0002 0.999
Sex 0.215 0.1
Disease duration 0.103 0.432
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Figure 6. Side eﬀects in patients of the studied groups.
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Regarding side eﬀects, there was hyperpigmentation,
pain and ulceration in all the studied groups. However,
pain was signiﬁcantly decreased in group IB compared to
group IA, ulceration was signiﬁcantly decreased in group
II than in group I, while pain after injection was increased
in group II than in group I (Fig. 6).3.5. Relapse in the studied groups
Regarding relapse, there was relapse in 12 patients
(40%) of group IA, in 14 patients (46.67%) of group IB
and no relapse occurred in any patients of group II
(Table 2).4. Discussion
Keloids and hypertrophic scars are ﬁbrotic conditions
that represent a model of altered wound healing with
overproduction of extracellular matrix and marked
proliferation of ﬁbroblasts. Their exact etiology and
pathophysiology is still poorly understood. No single
Table 2
Relapse of keloids & hypertrophic scars in all studied groups.
Time of relapse
(month)
Group IA Group IB Group IC
N % N % N %
1 2 6.67 4 13.33 0 0.00
2 0 0.00 4 13.33 0 0.00
3 6 20.00 2 6.67 0 0.00
4 2 6.67 0 0.00 0 0.00
5 0 0.00 0 0.00 0 0.00
6 2 6.67 4 13.33 0 0.00
Total 12 40.00 14 46.67 0 0.00
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2008; Trisliana Perdanasari et al., 2014). The aim of this
study was to evaluate the eﬃcacy and safety of intrale-
sional injection of 5-ﬂuorouracil and bleomycin in the
treatment of keloids and hypertrophic scars. It was not
possible to use a double-blind study design in this study
due to diﬀerence in the storage precautions of bleomycin
from that of 5-FU as bleomycin is stored at 4 C while
5-FU should not be freezed.
Five-ﬂuorouracil is an anti-metabolite that suppresses
cell division and produces growth arrest at any stage of
the cell cycle. It has been shown to inhibit ﬁbroblast prolif-
eration. So, it has been used intralesionally to treat keloids
and hypertrophic scars with good therapeutic results
(Asilian et al., 2006).
In the present study, intralesional injection of 5-FU
resulted in a signiﬁcant improvement in vascularity, pliabil-
ity and height while worsening in the pigmentation. These
results were in agreement with Nanda and Reddy (2004)
who had given intralesional 5-FU (50 mg/ml) to 28 patients
with keloids at weekly intervals. The total dose ranged
from 0.5 to 2 ml per session with a maximum number of
12 sessions and follow-up was done at 24 weeks. The
improvement was more than 50% in the majority of the
patients. Also, the results in the present study are in agree-
ment with Kontochristopoulos et al. (2005) who treated
twenty patients once weekly with intralesional injections
of 5-FU (50 mg /ml) at 0.2–0.4 ml/ cm2. Injections were
spaced at a 1 cm interval. The maximum dose was 2 ml
per session. All patients were followed up for 12 months,
or until recurrence was noted. Of the twenty patients, 17
(85%) showed more than 50% improvement. Moreover,
Gupta and Kalra (2002) treated twenty-four patients with
keloids with intralesional injections of 50–150 mg 5-FU
per week for a maximum of 16 injections. One third of
the patients showed more than 75% ﬂattening of the
keloids. Overall, about half of the patients showed more
than 50% ﬂattening of the treated keloids. The diﬀerence
in the present study and that in Gupta and Kalra (2002)
may be due to the diﬀerence in the number of sessions
and the dose used.
In group IB of the present study, the improvement was
better than that in group IA but the diﬀerence was statisti-
cally non signiﬁcant. Fitzpatrick (1999) was the ﬁrst to useTAC/5-FU combination in the treatment of keloids and
hypertrophic scars. He reported a 9-year experience admin-
istering more than 5000 injections of 5-FU to more than
1000 patients. He found that by mixing 1 mg/ml TAC with
5-FU, the eﬃcacy was improved and injections were less
painful. Also, he found that injection at weekly intervals
was better than monthly. He used pulsed dye laser in com-
bination with 5-FU injection .The results of his study were
over 90% improvement in most patients . The diﬀerence
between the present study and that of Fitzpatrick (1999)
may be due to the use of pulsed dye laser (PDL) in combi-
nation with 5-FU injection.
Also, the results of the present study were in agreement
with those of a study by Asilian et al. (2006) in which 69
patients of keloids and hypertrophic scars were randomly
assigned into three groups. In one group, intralesional
TAC was used, in the second intralesional TAC+5-FU
was used, in the third TAC+5-FU injections were followed
by pulsed-dye laser. All groups showed an acceptable
improvement in nearly all measures, but in comparison
between groups, there was a statistically more signiﬁcant
improvement in the TAC+5-FU and TAC+5-FU + PDL
groups. Also, Darougheh et al. (2007) had given a combi-
nation of intralesional TAC and 5-FU to twenty patients
with keloids and hypertrophic scars at weekly intervals
for 8 weeks. A good to excellent improvement was reported
by 55% of the patients as evidenced by an acceptable
improvement in nearly all parameters except pruritus and
percentage of itching reduction.
In the present study, multiple intralesional injections of
bleomycin produced a signiﬁcant improvement in vascular-
ity, pliability and height while worsening pigmentation
compared to 5-FU injection. These results were in agree-
ment with those of Saray and Gu¨lec¸ (2005) who used der-
mojet injection of bleomycin to treat 14 patients with
keloids and hypertrophic scars that had not responded to
intralesional injection of TAC. 73% of the lesions showed
complete ﬂattening, 7% showed highly signiﬁcant ﬂatten-
ing, 13% showed signiﬁcant ﬂattening and 7% showed
moderate ﬂattening.
Espan˜a et al. (2001) used intralesional bleomycin injec-
tion to treat keloids and hypertrophic scars in 13 patients
using multiple puncture method. The dose applied was
2 ml/cm2 with a maximum of 6 ml per session. Complete
ﬂattening was seen in 6 patients, highly signiﬁcant ﬂatten-
ing (>90%) was observed in 6 patients, and signiﬁcant ﬂat-
tening (75–90%) in 1 patient. Also, Aggarwal et al. (2008)
used bleomycin by multiple superﬁcial puncture technique
to treat ﬁfty patients with keloids and hypertrophic scars.
Three applications were given at an interval of ﬁfteen days
followed by a fourth and ﬁnal application two months after
the last application. This resulted in complete ﬂattening in
22 patients (44%), signiﬁcant ﬂattening in 11 patients
(22%), adequate ﬂattening in 7 patients (14%) and no ﬂat-
tening in 10 patients (20%). The diﬀerence between the pre-
sent study and that of Aggarwal et al. (2008) may be due to
the diﬀerence in the methods of injection. It could be
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eﬀective than the superﬁcial puncture techniques.
Naeini et al. (2006) treated 45 patients with keloids and
hypertrophic scars. They were divided into two groups;
group A was treated by bleomycin tattoo, group B was
treated with cryotherapy combined with intralesional
TAC. They were given four therapeutic sessions at a one-
month interval. Therapeutic response in lesions less than
100 mm2 was higher than 88% in both groups but in larger
lesions, the response to bleomycin was signiﬁcantly better
than cryotherapy combined with TAC.
In the present study, there was recurrence during the fol-
low up period in 12 (40%) patients of group IA and in 14
(46.67%) patients of group IB. These results were in agree-
ment with those of Kontochristopoulos et al. (2005) who
noted recurrence in 47% of patients who responded to
treatment within 1 year. However, Nanda and Reddy
(2004) observed no recurrence of symptoms or the lesion
during the follow-up period of 24 weeks in any of the
patients.
In group II, there was no recurrence during the follow
up period. This was in agreement with that of Saray and
Gu¨lec¸ (2005) who followed up their patients for 19 months
after treatment and observed no recurrence of the lesions.
Also, Bodokh and Brun (1996) used bleomycin inﬁltration
and observed no recurrence in any patients. On the other
hand, Espan˜a et al. (2001) observed recurrence in 15% of
patients 10 months after the last inﬁltration of bleomycin.
In the present study, no correlation between clinical
response and age, sex or duration of keloids was found.
This was in line with that of Nanda and Reddy (2004)
who observed no correlation between duration of keloid
and response to treatment. Also, Naeini et al. (2006) found
no correlation between location or duration of lesions
and the therapeutic response. On the contrary,
Kontochristopoulos et al. (2005) found a correlation
between duration of keloids and recurrence. He observed
that the response was low in older lesions.
Regarding the side eﬀects in the present study, there
were hyperpigmentation, ulceration and pain. In group
IA, hyperpigmentation was present in 20 patients
(66.67%), ulceration was present in 18 patients (60%) and
pain at the injection site was present in 22 patients
(73.33%). Nanda and Reddy (2004) found that pain, burn-
ing sensation and ulceration were the main adverse eﬀects.
Pain was found in 100% of patients, ulceration was found
in 20% of patients and burning sensation in 7% of patients.
The diﬀerence may be due to performing the injection with-
out local anesthesia. Also, Kontochristopoulos et al. (2005)
found that pain, hyperpigmentation and ulceration were
the main adverse eﬀects. Pain was found in all patients as
the injection was done without local anesthesia, ulceration
was observed in 6 out of 20 patients and hyperpigmenta-
tion in all patients.
In group IB, hyperpigmentation was present in 18
patients (60%), ulceration was present in 18 patients(60%) and pain at the injection site was present in 10
patients (33.33%). The side eﬀects in group IB were nearly
the same as group IA except for pain which was signiﬁ-
cantly decreased in group IB. In a study by Darougheh
et al. (2007), no adverse eﬀects were seen in the
TAC+5-FU group. In group II of the present study, hyper-
pigmentation was present in 42 patients (70%), ulceration
was present in 14 patients (21.33%) and pain at the injec-
tion site was present in all patients (100%).
In a study by Espan˜a et al. (2001), four patients had skin
type II and nine patients had skin type III. They detected
slight residual hyperpigmentation in two patients with skin
type III. In the present study, all patients had skin types
III, IV and V. The diﬀerence between the present study
and that of Espan˜a et al. (2001) may be due to the diﬀer-
ence in skin types of patients in the two studies.
In conclusion, intralesional injection of bleomycin was
more eﬀective and better in remission than intralesional
5-FU injection in the treatment of keloids and hyper-
trophic scars regardless of patient’s age, sex, disease dura-
tion or site of lesion.Conﬂict of interest
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